Aditya Shreenivas, MD, MS, discusses the clinical trial that led to the FDA approval of penpulimab in nasopharyngeal carcinoma.
Aditya Shreenivas, MD, MS
Advertisement
Aditya Shreenivas, MD, MS, is an assistant professor in the Department of Medical Oncology & Therapeutics Research at City of Hope.
Articles by Aditya Shreenivas, MD, MS
Aditya Shreenivas, MD, MS, discusses findings from the clinical trial supporting the FDA approval of penpulimab in nasopharyngeal carcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
